

Jack A Schalken

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1568922/jack-a-schalken-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

401
papers

18,898
citations

71
h-index

124
g-index

474
ext. papers

20,716
ext. citations

5.3
avg, IF

6.33
L-index

#	Paper	IF	Citations
401	Liquid biopsy in bladder cancer: State of the art and future perspectives.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 170, 103577	7	7
400	First results of the PROMPT trial: Precision oncology allocation in patients with early castration-resistant prostate cancer following routine molecular profiling.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 40-40	2.2	
399	Carbon sources and pathways for citrate secreted by human prostate cancer cells determined by NMR tracing and metabolic modeling.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119, e2024357119	11.5	2
398	Predictive and prognostic biomarker identification in a large cohort of androgen receptor-positive salivary duct carcinoma patients scheduled for combined androgen blockade.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 6071-6071	2.2	
397	Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment. <i>Molecular Oncology</i> , 2021 , 15, 2453-2465	7.9	4
396	Androgen receptor signalling confers clonogenic and migratory advantages in urothelial cell carcinoma of the bladder. <i>Molecular Oncology</i> , 2021 , 15, 1882-1900	7.9	2
395	Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 1110-1119	6.2	8
394	Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer. <i>World Journal of Urology</i> , 2021 , 39, 3789-3797	4	3
393	Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 2021 , 148, 385-395	7.5	13
392	Prostate Cancer Liquid Biopsy Biomarkers' Clinical Utility in Diagnosis and Prognosis. <i>Cancers</i> , 2021 , 13,	6.6	7
391	Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade. <i>Cancers</i> , 2021 , 13,	6.6	4
390	Molecular Phenotyping of AR Signaling for Predicting Targeted Therapy in Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 721659	5.3	0
389	RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer.. <i>Cancers</i> , 2021 , 13,	6.6	1
388	Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis. <i>Cancers</i> , 2020 , 12,	6.6	8
387	Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study. <i>Clinical Chemistry</i> , 2020 , 66, 842-851	5.5	12
386	Introducing PIONEER: a project to harness big data in prostate cancer research. <i>Nature Reviews Urology</i> , 2020 , 17, 351-362	5.5	7
385	A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNA-Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate Cancer.. <i>JCO Precision Oncology</i> , 2020 , 4, 714-729	3.6	7

384	Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study. <i>Theranostics</i> , 2020 , 10, 2273-2283	12.1	21
383	Validation of a 2-gene mRNA urine test for the detection of α G2 prostate cancer in an opportunistic screening population. <i>Prostate</i> , 2020 , 80, 500-507	4.2	6
382	Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients. <i>International Journal of Cancer</i> , 2020 , 146, 3196-3206	7.5	18
381	Improving the barrier function of damaged cultured urothelium using chondroitin sulfate. <i>Neurourology and Urodynamics</i> , 2020 , 39, 558-564	2.3	4
380	Prognostic value of PSMA, c-MET and E-cadherin in salivary duct carcinoma. <i>Oral Oncology</i> , 2020 , 110, 105018	4.4	2
379	Pyruvate-lactate exchange and glucose uptake in human prostate cancer cell models. A study in xenografts and suspensions by hyperpolarized [1- C]pyruvate MRS and [F]FDG-PET. <i>NMR in Biomedicine</i> , 2020 , 33, e4362	4.4	4
378	Polyisocyanide Hydrogels as a Tunable Platform for Mammary Gland Organoid Formation. <i>Advanced Science</i> , 2020 , 7, 2001797	13.6	18
377	Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review. <i>Cancer Treatment Reviews</i> , 2020 , 89, 102069	14.4	12
376	Prior PSMA PET-CT Imaging and Hounsfield Unit Impact on Tumor Yield and Success of Molecular Analyses from Bone Biopsies in Metastatic Prostate Cancer. <i>Cancers</i> , 2020 , 12,	6.6	1
375	Clinical utility of emerging biomarkers in prostate cancer liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 219-230	3.8	23
374	Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis. <i>Oncogene</i> , 2019 , 38, 3696-3709	9.2	14
373	A Four-Group Urine Risk Classifier for Predicting Outcome in Prostate Cancer Patients. <i>BJU International</i> , 2019 , 124, 609	5.6	17
372	Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma. <i>European Journal of Cancer</i> , 2019 , 110, 62-70	7.5	31
371	Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study. <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 101-109	6.2	41
370	Cost-effectiveness of a two-gene urine biomarker assay in MRI strategies for the initial detection of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 91-91	2.2	0
369	Urinary Molecular Biomarker Test Impacts Prostate Biopsy Decision Making in Clinical Practice. <i>Urology Practice</i> , 2019 , 6, 256-261	0.8	2
368	Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate Biopsy. <i>Journal of Urology</i> , 2019 , 202, 256-263	2.5	40
367	Clinically significant Prostate Cancer diagnosed using a urinary molecular biomarker-based risk score: two case reports. <i>BMC Urology</i> , 2019 , 19, 124	2.2	1

366	The importance of targeting intracrinology in prostate cancer management. <i>World Journal of Urology</i> , 2019 , 37, 751-757	4	0
365	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. <i>Annals of Oncology</i> , 2019 , 30, e3	10.3	12
364	Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients. <i>Prostate</i> , 2018 , 78, 336-342	4.2	31
363	Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Therapeutic Drug Monitoring</i> , 2018 , 40, 222-229	3.2	8
362	Urine cell-based DNA methylation classifier for monitoring bladder cancer. <i>Clinical Epigenetics</i> , 2018 , 10, 71	7.7	30
361	Correlates of response to anti-PD-1 immune checkpoint blockade (ICB) in mismatch repair proficient (MMRp) and deficient (MMRd) patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5036-5036	2.2	1
360	Immunological and genomic correlates of response to anti-PD1 checkpoint therapy in mismatch proficient and deficient patients with metastasized castration resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 248-248	2.2	5
359	Genomic Markers in Prostate Cancer Decision Making. <i>European Urology</i> , 2018 , 73, 572-582	10.2	122
358	In-depth assessment of metastatic prostate cancer with high tumour mutational burden. <i>Annals of Oncology</i> , 2018 , 29, viii274	10.3	3
357	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology</i> , 2018 , 19, e696-e708	21.7	59
356	Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy. <i>BJU International</i> , 2017 , 119, 74-81	5.6	13
355	Biomarkers for Prostate Cancer 2017 , 77-96		
354	Urothelium update: how the bladder mucosa measures bladder filling. <i>Acta Physiologica</i> , 2017 , 220, 201-217	3.67	16
353	miRNA-520f Reverses Epithelial-to-Mesenchymal Transition by Targeting and. <i>Cancer Research</i> , 2017 , 77, 2008-2017	10.1	39
352	Molecular biomarkers to guide precision medicine in localized prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2017 , 17, 791-804	3.8	15
351	Analytical challenges in quantifying abiraterone with LC-MS/MS in human plasma. <i>Biomedical Chromatography</i> , 2017 , 31, e3986	1.7	15
350	Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model. <i>BJU International</i> , 2017 , 120, 659-665	5.6	37
349	Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions. <i>Prostate Cancer and Prostatic Diseases</i> , 2017 , 20, 12-19	6.2	75

348	Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. <i>Oncotarget</i> , 2017 , 8, 50804-50813	3.3	27
347	A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection. <i>Prostate</i> , 2017 , 77, 1401-1407	4.2	49
346	Label retention and stem cell marker expression in the developing and adult prostate identifies basal and luminal epithelial stem cell subpopulations. <i>Stem Cell Research and Therapy</i> , 2017 , 8, 95	8.3	9
345	Analytical validation of an mRNA-based urine test to predict the presence of high-grade prostate cancer. <i>Translational Medicine Communications</i> , 2017 , 2,	4	5
344	A short-term intervention with selenium affects expression of genes implicated in the epithelial-to-mesenchymal transition in the prostate. <i>Oncotarget</i> , 2017 , 8, 10565-10579	3.3	13
343	A five-gene expression signature to predict progression in T1G3 bladder cancer. <i>European Journal of Cancer</i> , 2016 , 64, 127-36	7.5	50
342	TRPV4 channels in the human urogenital tract play a role in cell junction formation and epithelial barrier. <i>Acta Physiologica</i> , 2016 , 218, 38-48	5.6	13
341	Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016 , 54, 483-92	5.9	34
340	Validatie van een nieuwe urinetest voor klinisch significante prostaatkanker. <i>Tijdschrift Voor Urologie</i> , 2016 , 6, 34-43	0.2	
339	Development and validation of a bioanalytical assay on LC/MS/MS to quantify enzalutamide and N-desmethylenzalutamide in human plasma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 330-330	2.2	1
338	XRP44X, an Inhibitor of Ras/Erk Activation of the Transcription Factor Elk3, Inhibits Tumour Growth and Metastasis in Mice. <i>PLoS ONE</i> , 2016 , 11, e0159531	3.7	12
337	Elevated HOXC6/DLX1 mRNA biomarker levels in urine to help select patients at increased risk for high-grade prostate cancer detection upon prostate biopsy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 31-31 ^{2.2}	2.2	1
336	Analytical challenges in quantitative analysis (LC/MS/MS) of abiraterone: A validated assay to determine abiraterone in human plasma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 329-329	2.2	
335	Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 1369-1380	6.2	54
334	Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. <i>European Urology</i> , 2016 , 70, 740-748	10.2	215
333	TRPV4 mediates afferent pathways in the urinary bladder. A spinal c-fos study showing TRPV1 related adaptations in the TRPV4 knockout mouse. <i>Pflugers Archiv European Journal of Physiology</i> , 2016 , 468, 1741-9	4.6	7
332	Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2016 , 117, 215-25	5.6	66
331	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. <i>Annals of Oncology</i> , 2015 , 26, 1589-604 ^{10.3}	10.3	220

330	The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 202.e19-28	2.8	7
329	Genomic Predictors of Outcome in Prostate Cancer. <i>European Urology</i> , 2015 , 68, 1033-44	10.2	136
328	Involvement of orphan nuclear receptor COUP-TFII in cadherin-6 and cadherin-11 regulation: implications in development and cancer. <i>Mechanisms of Development</i> , 2015 , 136, 64-72	1.7	11
327	The need for a personalized approach for prostate cancer management. <i>BMC Medicine</i> , 2015 , 13, 109	11.4	4
326	Dutasteride and enzalutamide synergistically suppress prostate tumor cell proliferation. <i>Journal of Urology</i> , 2015 , 193, 1023-9	2.5	14
325	The role of HOXC6 in prostate cancer development. <i>Prostate</i> , 2015 , 75, 1868-76	4.2	33
324	Contemporary approaches to prostate cancer management. <i>Future Oncology</i> , 2015 , 11, 2735-6	3.6	
323	Direct dynamic measurement of intracellular and extracellular lactate in small-volume cell suspensions with ¹³ C hyperpolarised NMR. <i>NMR in Biomedicine</i> , 2015 , 28, 1040-8	4.4	12
322	Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 3061-70	12.9	155
321	The Role of Biomarkers and Genetics in the Diagnosis of Prostate Cancer. <i>European Urology Focus</i> , 2015 , 1, 99-108	5.1	6
320	Inflammation in the Pathophysiology of Benign Prostatic Hypertrophy. <i>European Urology Supplements</i> , 2015 , 14, e1455-e1458	0.9	9
319	Prostate cancer biomarker profiles in urinary sediments and exosomes. <i>Journal of Urology</i> , 2014 , 191, 1132-8	2.5	82
318	Clinical use of novel urine and blood based prostate cancer biomarkers: a review. <i>Clinical Biochemistry</i> , 2014 , 47, 889-96	3.5	91
317	Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. <i>European Urology</i> , 2014 , 65, 534-42	10.2	261
316	Self-reported acne is not associated with prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 941-5	2.8	3
315	KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment. <i>Prostate</i> , 2014 , 74, 1222-30	4.2	25
314	Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer. <i>Therapeutic Advances in Urology</i> , 2014 , 6, 245-52	3.2	11
313	Prevention and early detection of prostate cancer. <i>Lancet Oncology</i> , 2014 , 15, e484-92	21.7	277

312	An update of the interstitial cell compartment in the normal human bladder. <i>BioMed Research International</i> , 2014 , 2014, 464217	3	4
311	Noncoding RNAs as novel biomarkers in prostate cancer. <i>BioMed Research International</i> , 2014 , 2014, 591703	3	63
310	Alterations of the myovesical plexus of the human overactive detrusor. <i>BioMed Research International</i> , 2014 , 2014, 754596	3	2
309	Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer. <i>BJU International</i> , 2014 , 114, 608-16	5.6	20
308	Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy. <i>Prostate International</i> , 2014 , 2, 105-13	3.4	16
307	Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis. <i>Prostate</i> , 2013 , 73, 113-20	4.2	41
306	Next Generation Screening Tests 2013 , 347-354		
305	Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. <i>European Urology</i> , 2013 , 63, 201-9	10.2	96
304	MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. <i>Oncogene</i> , 2013 , 32, 277-85	9.2	183
303	The long and winding road to FDA approval of a novel prostate cancer test: our story. <i>Clinical Chemistry</i> , 2013 , 59, 32-4	5.5	19
302	A new, straightforward ex vivo organoid bladder mucosal model for preclinical research. <i>Journal of Urology</i> , 2013 , 190, 341-9	2.5	5
301	Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer. <i>Molecular Medicine</i> , 2013 , 18, 1449-55	6.2	62
300	Urinary biomarkers for prostate cancer: a review. <i>Asian Journal of Andrology</i> , 2013 , 15, 333-9	2.8	58
299	Recurrent gene fusions in prostate cancer: their clinical implications and uses. <i>Current Urology Reports</i> , 2013 , 14, 214-22	2.9	24
298	The distribution and function of chondroitin sulfate and other sulfated glycosaminoglycans in the human bladder and their contribution to the protective bladder barrier. <i>Journal of Urology</i> , 2013 , 189, 336-42	2.5	37
297	Value of PCA3 to predict biopsy outcome and its potential role in selecting patients for multiparametric MRI. <i>International Journal of Molecular Sciences</i> , 2013 , 14, 11347-55	6.3	21
296	Prostate cancer susceptibility genes on 8p21-23 in a Dutch population. <i>Prostate Cancer and Prostatic Diseases</i> , 2013 , 16, 248-53	6.2	5
295	High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer. <i>BJU International</i> , 2013 , 111, 836-42	5.6	6

294	Molecular Identification of the Indolent Versus Lethal Tumor 2013 , 81-94		
293	The role of genetic markers in the management of prostate cancer. <i>European Urology</i> , 2012 , 62, 577-87	10.2	86
292	Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. <i>Journal of Urology</i> , 2012 , 187, 795-801	2.5	97
291	2104 PROSPECTIVE MULTICENTER EVALUATION OF PCA3 AND TMPRSS2-ERG GENE FUSIONS AS DIAGNOSTIC AND PROGNOSTIC BIOMARKERS FOR PROSTATE CANCER. <i>Journal of Urology</i> , 2012 , 187,	2.5	2
290	Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer. <i>Prostate</i> , 2012 , 72, 789-802	4.2	21
289	DC-SCRIPT: AR and VDR regulator lost upon transformation of prostate epithelial cells. <i>Prostate</i> , 2012 , 72, 1708-17	4.2	9
288	An integrated framework of personalized medicine: from individual genomes to participatory health care. <i>Croatian Medical Journal</i> , 2012 , 53, 301-3	1.6	21
287	Personalized cancer therapy for urological cancers: from bench to bedside and back. <i>Advances in Urology</i> , 2012 , 2012, 298105	1.6	
286	Personalized management in low-risk prostate cancer: the role of biomarkers. <i>Prostate Cancer</i> , 2012 , 2012, 327104	1.9	9
285	PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. <i>Journal of Immunotherapy</i> , 2012 , 35, 169-78	5	203
284	Tubulin tyrosine ligase like 12, a TTL family member with SET- and TTL-like domains and roles in histone and tubulin modifications and mitosis. <i>PLoS ONE</i> , 2012 , 7, e51258	3.7	17
283	How accurate is our prediction of biopsy outcome? PCA3-based nomograms in personalized diagnosis of prostate cancer. <i>Central European Journal of Urology</i> , 2012 , 65, 110-2	0.9	4
282	Biomarkers for Prostate Cancer 2012 , 55-68		
281	A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. <i>Nature Genetics</i> , 2011 , 43, 1098-103	36.3	203
280	Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer. <i>American Journal of Pathology</i> , 2011 , 178, 525-36	5.8	80
279	Adherence junctions and cadherin-11 in normal and overactive human detrusor smooth muscle cells. <i>Journal of Urology</i> , 2011 , 185, 1946-51	2.5	1
278	The mechanoreceptor TRPV4 is localized in adherence junctions of the human bladder urothelium: a morphological study. <i>Journal of Urology</i> , 2011 , 186, 1121-7	2.5	70
277	Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. <i>Molecular Medicine</i> , 2011 , 17, 657-64	6.2	88

276	Genetic marker polymorphisms on chromosome 8q24 and prostate cancer in the Dutch population: DG8S737 may not be the causative variant. <i>European Journal of Human Genetics</i> , 2011 , 19, 118-20	5.3	38
275	Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. <i>European Urology</i> , 2011 , 60, 1045-54	10.2	119
274	Prevalence of human xenotropic murine leukemia virus-related gammaretrovirus (XMRV) in Dutch prostate cancer patients. <i>Prostate</i> , 2011 , 71, 415-20	4.2	42
273	Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. <i>Prostate</i> , 2011 , 71, 1701-9	4.2	19
272	The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?. <i>BJU International</i> , 2010 , 106, 1143-7	5.6	49
271	Transmembrane protease serine 2 in prostate cancer. <i>BJU International</i> , 2010 , 105, 1490-2	5.6	3
270	Genetic correction of PSA values using sequence variants associated with PSA levels. <i>Science Translational Medicine</i> , 2010 , 2, 62ra92	17.5	125
269	The role of PCA3 testing in patients with a raised prostate-specific antigen level after Greenlight photoselective vaporization of the prostate. <i>Journal of Endourology</i> , 2010 , 24, 1821-4	2.7	10
268	PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis. <i>Cancers</i> , 2010 , 2, 1432-40	6.6	8
267	1036 THE UROTHELIAL CELL-LINE RT4 EXPRESSES A GLYCOSAMINOGLYCAN (GAG) LAYER ON ITS OUTER SURFACE; AN IN VITRO MODEL FOR THE BLADDER GAG-LAYER. <i>Journal of Urology</i> , 2010 , 183,	2.5	1
266	Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review. <i>European Urology Supplements</i> , 2010 , 9, 675-691	0.9	13
265	Stem cell characteristics in prostate cancer cell lines. <i>European Urology</i> , 2010 , 57, 246-54	10.2	88
264	Reply to Juan Morote's Letter to the Editor re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. <i>Eur Urol</i> 2009;56:659-68. <i>European Urology</i> , 2010 , 57, e2-e3	10.2	0
263	Reply to Tomasz Drewa's Letter to the Editor re: Minja J. Pfeiffer, Jack A. Schalken. Stem Cell Characteristics in Prostate Cancer Cell Lines. <i>Eur Urol</i> 2010;57:246-55. <i>European Urology</i> , 2010 , 57, e27	10.2	
262	Testosterone measurement in patients with prostate cancer. <i>European Urology</i> , 2010 , 58, 65-74	10.2	31
261	Tubulin tyrosine ligase like 12 links to prostate cancer through tubulin posttranslational modification and chromosome ploidy. <i>International Journal of Cancer</i> , 2010 , 127, 2542-53	7.5	31
260	Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. <i>Prostate</i> , 2010 , 70, 10-6	4.2	128
259	Differential expression of PCA3 and its overlapping PRUNE2 transcript in prostate cancer. <i>Prostate</i> , 2010 , 70, 70-8	4.2	41

258	An in vitro model for preclinical testing of endocrine therapy combinations for prostate cancer. <i>Prostate</i> , 2010 , 70, 1524-32	4.2	15
257	Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2009 , 12, 241-6	6.2	22
256	Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1. <i>Carcinogenesis</i> , 2009 , 30, 698-705	4.6	62
255	Editorial comment on: Mutations in the AXIN1 gene in advanced prostate cancer. <i>European Urology</i> , 2009 , 56, 494	10.2	
254	Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. <i>European Urology</i> , 2009 , 56, 659-67	10.2	142
253	ETS gene fusions in prostate cancer: from discovery to daily clinical practice. <i>European Urology</i> , 2009 , 56, 275-86	10.2	279
252	Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study. <i>Prostate</i> , 2009 , 69, 1624-34	4.2	20
251	In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. <i>Prostate</i> , 2009 , 69, 1683-93	4.2	73
250	Reply to the letter to the editor: Differential expression of PCA3 and BMCC1 in Prostate Cancer, by Lavin M.F., Clarke R. and R.A. Gardiner. <i>Prostate</i> , 2009 , 69, 1715-1715	4.2	
249	Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. <i>Nature Genetics</i> , 2009 , 41, 221-7	36.3	509
248	The use of PCA3 in the diagnosis of prostate cancer. <i>Nature Reviews Urology</i> , 2009 , 6, 255-61	5.5	166
247	Towards Early and More Specific Diagnosis of Prostate Cancer? Beyond PSA: New Biomarkers Ready for Prime Time. <i>European Urology Supplements</i> , 2009 , 8, 97-102	0.9	2
246	PCA3 2009 , 233-241		1
245	Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues. <i>BJU International</i> , 2008 , 102, 177-82	5.6	18
244	Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. <i>European Urology</i> , 2008 , 54, 1081-8	10.2	325
243	Words of wisdom. Re: phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. <i>European Urology</i> , 2008 , 54, 1438-9	10.2	2
242	Highlights on Prostate Cancer from Urological and Oncological Congresses in 2007. <i>European Urology Supplements</i> , 2008 , 7, 460-476	0.9	0
241	IMPROVED PREDICTION OF PROSTATE BIOPSY OUTCOME USING PCA3, TMPRSS2:ERG GENE FUSIONS AND SERUM PSA. <i>Journal of Urology</i> , 2008 , 179, 725-725	2.5	3

240	Alcohol consumption and mutations or promoter hypermethylation of the von Hippel-Lindau gene in renal cell carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 3543-50	4	8
239	Carotenoid and vitamin intake, von Hippel-Lindau gene mutations and sporadic renal cell carcinoma. <i>Cancer Causes and Control</i> , 2008 , 19, 125-34	2.8	23
238	Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. <i>Prostate</i> , 2008 , 68, 1215-22	4.2	71
237	Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 5103-8	12.9	273
236	Prognostic value of p53 for high risk superficial bladder cancer with long-term followup. <i>Journal of Urology</i> , 2007 , 177, 80-3	2.5	32
235	Molecular PCA3 diagnostics on prostatic fluid. <i>Prostate</i> , 2007 , 67, 881-7	4.2	44
234	The prognostic value of E-cadherin and the cadherin-associated molecules alpha-, beta-, gamma-catenin and p120ctn in prostate cancer specific survival: a long-term follow-up study. <i>Prostate</i> , 2007 , 67, 1432-8	4.2	52
233	Molecular aspects of hormone-independent prostate cancer. <i>BJU International</i> , 2007 , 100 Suppl 2, 52-5	5.6	9
232	The prognostic value of E-cadherin, alpha-, beta- and gamma-catenin in bladder cancer patients who underwent radical cystectomy. <i>International Journal of Urology</i> , 2007 , 14, 789-94	2.3	17
231	A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. <i>BMC Genomics</i> , 2007 , 8, 84	4.5	36
230	Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. <i>European Urology</i> , 2007 , 52, 464-8	10.2	29
229	Cadherin-11 is expressed in detrusor smooth muscle cells and myofibroblasts of normal human bladder. <i>European Urology</i> , 2007 , 52, 1213-21	10.2	36
228	Editorial comment on: Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. <i>European Urology</i> , 2007 , 52, 1679	10.2	1
227	The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. <i>Clinical Cancer Research</i> , 2007 , 13, 939-43	12.9	153
226	Molecular markers for prostate cancer. <i>Cancer Letters</i> , 2007 , 249, 5-13	9.9	36
225	Prostate (Cancer) Stem Cells 2007 , 63-72		1
224	The prognostic value of E-cadherin, alpha-, beta-, and gamma-catenin in urothelial cancer of the upper urinary tract. <i>European Urology</i> , 2006 , 49, 839-45; discussion 845	10.2	28
223	The predictive value of p53, p27(kip1), and alpha-catenin for progression in superficial bladder carcinoma. <i>European Urology</i> , 2006 , 50, 76-82	10.2	19

222	Quantitative cytology on bladder wash versus voided urine: a comparison of results. <i>European Urology</i> , 2006 , 49, 1044-9; discussion 1049-50	10.2	5
221	hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis. <i>Cancer Research</i> , 2006 , 66, 3531-40	10.1	79
220	TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. <i>Cancer Research</i> , 2006 , 66, 10242-6	10.1	188
219	New Developments in the Pathobiology of Prostate Disease. <i>European Urology Supplements</i> , 2006 , 5, 729-736	0.9	3
218	Polymorphisms in the E-cadherin (CDH1) gene promoter and the risk of bladder cancer. <i>European Journal of Cancer</i> , 2006 , 42, 3219-27	7.5	21
217	Polymorphisms in the alpha1A-adrenoceptor gene do not modify the short- and long-term efficacy of alpha1-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. <i>BJU International</i> , 2006 , 97, 852-5	5.6	12
216	Cigarette smoking, von Hippel-Lindau gene mutations and sporadic renal cell carcinoma. <i>British Journal of Cancer</i> , 2006 , 95, 374-7	8.7	21
215	Androgen Receptor Mediated Growth of Prostate (Cancer). <i>European Urology Supplements</i> , 2005 , 4, 4-11	0.9	6
214	Molecular Diagnostics in Prostate Cancer. <i>EAU Update Series</i> , 2005 , 3, 200-213		9
213	Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. <i>Journal of Urology</i> , 2005 , 173, 1375-80	2.5	76
212	Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. <i>Urology</i> , 2005 , 66, 35-63	1.6	314
211	Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. <i>Urology</i> , 2005 , 66, 64-74	1.6	143
210	Hypertension, antihypertensives and mutations in the Von Hippel-Lindau gene in renal cell carcinoma: results from the Netherlands Cohort Study. <i>Journal of Hypertension</i> , 2005 , 23, 1997-2004	1.9	22
209	Validation of molecular targets in prostate cancer. <i>BJU International</i> , 2005 , 96 Suppl 2, 23-9	5.6	9
208	Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project. <i>European Urology</i> , 2005 , 48, 1031-41	10.2	36
207	Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. <i>BMC Cancer</i> , 2005 , 5, 57	4.8	86
206	Identification of androgen-responsive genes that are alternatively regulated in androgen-dependent and androgen-independent rat prostate tumors. <i>Genes Chromosomes and Cancer</i> , 2005 , 43, 273-83	5	9
205	CDC91L1 (PIG-U) mRNA expression in urothelial cell carcinomas. <i>International Journal of Cancer</i> , 2005 , 116, 282-4	7.5	6

204	Molecular prostate cancer pathology: current issues and achievements. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005 , 82-93		13
203	Role of complex cadherins in cell-cell adhesion evaluated by spheroid formation in renal cell carcinoma cell lines. <i>Oncology Reports</i> , 2004 , 11, 357	3.5	5
202	Applicability of biomarkers in the early diagnosis of prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2004 , 4, 513-26	3.8	42
201	Molecular and cellular prostate biology: origin of prostate-specific antigen expression and implications for benign prostatic hyperplasia. <i>BJU International</i> , 2004 , 93 Suppl 1, 5-9	5.6	16
200	Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia. <i>BJU International</i> , 2004 , 93 Suppl 1, 27-9	5.6	34
199	Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. <i>Oncogene</i> , 2004 , 23, 5624-31	9.2	151
198	Future opportunities for the diagnosis and treatment of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2004 , 7 Suppl 1, S8-S13	6.2	7
197	Intravesical gemcitabine: a phase 1 and pharmacokinetic study. <i>European Urology</i> , 2004 , 45, 182-6	10.2	37
196	Engineered FGF-2 expression induces glandular epithelial hyperplasia in the murine prostatic dorsal lobe. <i>European Urology</i> , 2004 , 46, 126-32	10.2	14
195	The effect of hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines. <i>European Urology</i> , 2004 , 46, 670-4	10.2	33
194	A rabbit model to tissue engineer the bladder. <i>Biomaterials</i> , 2004 , 25, 1657-61	15.6	57
193	Site-specific familial aggregation of prostate cancer. <i>International Journal of Cancer</i> , 2004 , 109, 611-7	7.5	21
192	Etiology and management of pelvic pain syndrome. <i>Urology</i> , 2004 , 63, 74	1.6	1
191	Activated Leukocyte Cell Adhesion Molecule (ALCAM) Expression is Associated with a Poor Prognosis for Bladder Cancer Patients. <i>UroOncology</i> , 2003 , 3, 121-129		18
190	DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. <i>European Urology</i> , 2003 , 44, 8-15; discussion 15-6	10.2	498
189	Rabbit urethra replacement with a defined biomatrix or small intestinal submucosa. <i>European Urology</i> , 2003 , 44, 266-71	10.2	40
188	Pharmacokinetics of intravesical gemcitabine: a preclinical study in pigs. <i>European Urology</i> , 2003 , 44, 615-9	10.2	11
187	Epithelial cell differentiation in the human prostate epithelium: implications for the pathogenesis and therapy of prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2003 , 46 Suppl, S3-10	7	53

186	Allelic imbalance in hereditary and sporadic prostate cancer. <i>Prostate</i> , 2003 , 54, 50-7	4.2	11
185	Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. <i>American Journal of Pathology</i> , 2003 , 162, 1529-37	5.8	136
184	Introduction: prostate cancer: from basic science to clinical application?. <i>Urology</i> , 2003 , 62, 1-2	1.6	34
183	Cellular and molecular biology of the prostate: stem cell biology. <i>Urology</i> , 2003 , 62, 11-20	1.6	123
182	New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. <i>Urology</i> , 2003 , 62, 34-43	1.6	116
181	The Androgen Cascade in Ageing Men: Blessing or Curse?. <i>European Urology Supplements</i> , 2003 , 2, 8-12	0.9	10
180	The transcription factor Net regulates the angiogenic switch. <i>Genes and Development</i> , 2003 , 17, 2283-97	12.6	53
179	Cell Adhesion Molecules in Genitourinary Cancer 2003 , 455-472		
178	Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. <i>Anticancer Research</i> , 2003 , 23, 3327-31	2.3	37
177	Tenascin expression in normal, hyperplastic, dysplastic and neoplastic canine mammary tissues. <i>Journal of Comparative Pathology</i> , 2002 , 126, 1-8	1	15
176	Single-nucleotide polymorphism in the E-cadherin gene promoter modifies the risk of prostate cancer. <i>International Journal of Cancer</i> , 2002 , 100, 683-5	7.5	54
175	JC virus strains indigenous to northeastern Siberians and Canadian Inuits are unique but evolutionally related to those distributed throughout Europe and Mediterranean areas. <i>Journal of Molecular Evolution</i> , 2002 , 55, 322-35	3.1	33
174	Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion. <i>Prostate</i> , 2002 , 51, 98-107	4.2	56
173	Treatment options in hormone resistant prostate cancer. <i>Annals of Oncology</i> , 2002 , 13 Suppl 4, 95-102	10.3	3
172	Analysis of expression of chorionic gonadotrophin transcripts in prostate cancer by quantitative Taqman and a modified molecular beacon RT-PCR. <i>Journal of Endocrinology</i> , 2002 , 172, 489-95	4.7	17
171	Renal cell carcinoma-associated G250 methylation and expression: in vivo and in vitro studies. <i>Urology</i> , 2002 , 60, 357-62	1.6	8
170	Morphogenic and tumorigenic potentials of the mammary growth hormone/growth hormone receptor system. <i>Molecular and Cellular Endocrinology</i> , 2002 , 197, 153-65	4.4	33
169	Canine prostate carcinoma: epidemiological evidence of an increased risk in castrated dogs. <i>Molecular and Cellular Endocrinology</i> , 2002 , 197, 251-5	4.4	139

168	IS INCREASED CAG REPEAT LENGTH IN THE ANDROGEN RECEPTOR GENE A RISK FACTOR FOR MALE SUBFERTILITY?. <i>Journal of Urology</i> , 2002 , 167, 621-623	2.5	38
167	DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. <i>Cancer Research</i> , 2002 , 62, 2695-8	10.1	426
166	Alcohol dehydrogenase type 3 (ADH3) and the risk of bladder cancer. <i>European Urology</i> , 2001 , 40, 509-14	10.2	11
165	The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. <i>European Urology</i> , 2001 , 39, 390-9	10.2	105
164	Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis. <i>BJU International</i> , 2001 , 88 Suppl 2, 35-42; discussion 49-50	5.6	48
163	Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues. <i>Prostate</i> , 2001 , 47, 14-20	4.2	3
162	Proliferative activity and branching morphogenesis in the human prostate: a closer look at pre- and postnatal prostate growth. <i>Prostate</i> , 2001 , 49, 132-9	4.2	21
161	Expression of basal cell keratins in human prostate cancer metastases and cell lines. <i>Journal of Pathology</i> , 2001 , 195, 563-70	9.4	85
160	Superficial and metachronous invasive bladder carcinomas are clonally related. <i>International Journal of Cancer</i> , 2001 , 93, 699-702	7.5	20
159	A novel method for the determination of basal gene expression of tissue-specific promoters: an analysis of prostate-specific promoters. <i>Cancer Gene Therapy</i> , 2001 , 8, 927-35	5.4	22
158	Canine balloon and signet-ring cell melanomas: a histological and immunohistochemical characterization. <i>Journal of Comparative Pathology</i> , 2001 , 125, 166-73	1	18
157	Immune response in hormonally-induced prostatic hyperplasia in the dog. <i>Veterinary Immunology and Immunopathology</i> , 2001 , 78, 297-303	2	13
156	Growth hormone induces tyrosyl phosphorylation of the transcription factors Stat5a and Stat5b in CMT-U335 canine mammary tumor cells. <i>Domestic Animal Endocrinology</i> , 2001 , 20, 123-35	2.3	10
155	Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. <i>Urology</i> , 2001 , 58, 367-71	1.6	70
154	Branching activity in the human prostate: a closer look at the structure of small glandular buds. <i>European Urology</i> , 2001 , 39, 222-31	10.2	9
153	Alterations in expression of cadherin-6 and E-cadherin during kidney development and in renal cell carcinoma. <i>European Urology</i> , 2000 , 38, 331-8	10.2	26
152	Complex cadherin expression in human prostate cancer cells. <i>International Journal of Cancer</i> , 2000 , 85, 446-450	7.5	112
151	Cell kinetics and differentiation after hormonal-induced prostatic hyperplasia in the dog. <i>Prostate</i> , 2000 , 44, 40-8	4.2	25

150	Partial sequencing and tissue distribution of the canine isoforms of steroid 5alpha-reductase type I and type II. <i>Prostate</i> , 2000 , 44, 233-9	4.2	9
149	Antitumor activity of the polyamine analog N(1), N(11)-diethylnorspermine against human prostate carcinoma cells. <i>Prostate</i> , 2000 , 44, 313-21	4.2	34
148	Quantitative measurement of telomerase reverse transcriptase (hTERT) mRNA in urothelial cell carcinomas. <i>International Journal of Cancer</i> , 2000 , 87, 217-220	7.5	62
147	Neural network-based digitized cell image diagnosis of bladder wash cytology. <i>Diagnostic Cytopathology</i> , 2000 , 23, 171-9	1.4	25
146	Models for studying benign prostatic hyperplasia. <i>Prostate Cancer and Prostatic Diseases</i> , 2000 , 3, 28-33	6.2	48
145	Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. <i>Laboratory Investigation</i> , 2000 , 80, 1251-8	5.9	133
144	Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2000 , 10, 153-9	2.8	77
143	Cadherin Switching in Human Prostate Cancer Progression. <i>Japanese Journal of Urology</i> , 2000 , 91, 92		2
142	Isolation and characterization of the promoter of the human prostate cancer-specific DD3 gene. <i>Journal of Biological Chemistry</i> , 2000 , 275, 37496-503	5.4	30
141	Coordinate recruitment of E-cadherin and ALCAM to cell-cell contacts by alpha-catenin. <i>Biochemical and Biophysical Research Communications</i> , 2000 , 267, 870-4	3.4	49
140	Lower incidence of urothelial cell carcinoma due to the concept of a clonal origin. <i>European Journal of Cancer</i> , 2000 , 36, 2385-9	7.5	7
139	Consecutive quantitative cytology in bladder cancer. <i>Urology</i> , 2000 , 56, 584-8	1.6	8
138	Presence of carcinoma in situ and high 2C-deviation index are the best predictors of invasive transitional cell carcinoma of the bladder in patients with high-risk Quanticyt. <i>Urology</i> , 2000 , 55, 363-7	1.6	13
137	Complex cadherin expression in human prostate cancer cells 2000 , 85, 446		4
136	Cell kinetics and differentiation after hormonal-induced prostatic hyperplasia in the dog 2000 , 44, 40		0
135	Cadherin switching in human prostate cancer progression. <i>Cancer Research</i> , 2000 , 60, 3650-4	10.1	283
134	Expression and molecular characterization of the growth hormone receptor in canine mammary tissue and mammary tumors. <i>Endocrinology</i> , 1999 , 140, 5907-14	4.8	25
133	Molecular genetics and epidemiology of prostate carcinoma. <i>Endocrine Reviews</i> , 1999 , 20, 22-45	27.2	130

132	A prospective randomized trial evaluating tissue effects of finasteride therapy in benign prostatic hyperplasia. <i>Prostate Cancer and Prostatic Diseases</i> , 1999 , 2, 277-281	6.2	13
131	Transient tenascin enhancement is an early event after androgen ablation in rat prostate. <i>Urological Research</i> , 1999 , 27, 9-15		4
130	Differential regulation of human alpha1-adrenoceptor subtypes. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1999 , 359, 439-46	3.4	33
129	Changes in cadherin-catenin complexes in the progression of human bladder carcinoma. <i>International Journal of Cancer</i> , 1999 , 82, 70-6	7.5	41
128	Mechanisms associated with abnormal E-cadherin immunoreactivity in human bladder tumors. <i>International Journal of Cancer</i> , 1999 , 83, 591-5	7.5	20
127	Molecular analysis of multifocal prostate cancer lesions. <i>Journal of Pathology</i> , 1999 , 188, 271-7	9.4	47
126	SELECTIVITY OF FINASTERIDE AS AN IN VIVO INHIBITOR OF 5 alpha-REDUCTASE ISOZYME ENZYMATIC ACTIVITY IN THE HUMAN PROSTATE. <i>Journal of Urology</i> , 1999 , 161, 332-337	2.5	60
125	Mammary growth hormone and tumorigenesis--lessons from the dog. <i>Veterinary Quarterly</i> , 1999 , 21, 111-5	8	28
124	DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. <i>Cancer Research</i> , 1999 , 59, 5975-9	10.1	710
123	Cell kinetics of prostate exocrine and neuroendocrine epithelium and their differential interrelationship: New perspectives. <i>Prostate</i> , 1998 , 36, 62-73	4.2	37
122	Identification and partial characterization of two steroid 5 alpha-reductase isozymes in the canine prostate. <i>Prostate</i> , 1998 , 34, 222-30	4.2	12
121	Identification of intermediate cell types by keratin expression in the developing human prostate. <i>Prostate</i> , 1998 , 34, 292-301	4.2	80
120	Expression of periglandular tenascin-C and basement membrane laminin in normal prostate, benign prostatic hyperplasia and prostate carcinoma. <i>BJU International</i> , 1998 , 81, 844-51	5.6	17
119	Genetic and molecular markers in the prognosis of bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 1998 , 4, 139-44	2.8	
118	MULTIFOCAL TRANSITIONAL CELL CANCER AND p53 MUTATION ANALYSIS. <i>Journal of Urology</i> , 1998 , 160, 124-125	2.5	7
117	Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer. <i>Urology</i> , 1998 , 51, 44-50	1.6	60
116	DETECTION OF ABNORMAL E-CADHERIN EXPRESSION BY SIMULATED PROSTATE BIOPSY. <i>Journal of Urology</i> , 1998 , 160, 1368-1372	2.5	6
115	Comparative analysis of p53 mutations in bladder washings and histologic specimens. <i>American Journal of Clinical Pathology</i> , 1998 , 110, 647-52	1.9	8

114	Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer. <i>European Urology</i> , 1998 , 33, 387-91	10.2	34
113	The Bard BTA test: its mode of action, sensitivity and specificity, compared to cytology of voided urine, in the diagnosis of superficial bladder cancer. <i>European Urology</i> , 1998 , 34, 99-106	10.2	31
112	A Novel Immunoenzymatic Technique to Demonstrate Multiple Antigens in Cells Based on Selective Destaining of Substrate Deposits and Its Application in Characterizing the Immunophenotype of Neuroendocrine Cells in the Human Prostate Epithelium. <i>Applied Immunohistochemistry & Molecular Morphology</i> , 1998 , 6, 69-76		5
111	Cell kinetics of prostate exocrine and neuroendocrine epithelium and their differential interrelationship: New perspectives 1998 , 36, 62		1
110	Intratumoral nuclear morphologic heterogeneity in prostate cancer. <i>Urology</i> , 1997 , 49, 652-7	1.6	23
109	Molecular cloning of an alternative human alphaE-catenin cDNA. <i>Biochemical and Biophysical Research Communications</i> , 1997 , 237, 177-81	3.4	2
108	Role of E boxes in the repression of E-cadherin expression. <i>Biochemical and Biophysical Research Communications</i> , 1997 , 241, 453-8	3.4	118
107	Differential expression of ferritin heavy chain in a rat transitional cell carcinoma progression model. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1997 , 1360, 39-44	6.9	8
106	New perspectives in the treatment of prostate cancer. <i>European Urology</i> , 1997 , 31 Suppl 2, 20-3	10.2	14
105	Rapid microwave-stimulated fixation of entire prostatectomy specimens. Biomed-II MPC Study Group. <i>Journal of Pathology</i> , 1997 , 183, 369-75	9.4	53
104	Suppression of invasive ability of highly metastatic rat prostate cancer by introduction of human chromosome 8. <i>Prostate</i> , 1997 , 31, 14-20	4.2	13
103	Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: correlation with metastatic behavior in vivo. <i>Prostate</i> , 1997 , 32, 196-204	4.2	37
102	Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer. <i>International Journal of Cancer</i> , 1997 , 74, 374-7	7.5	71
101	Decreased expression of alpha-catenin is associated with poor prognosis of patients with localized renal cell carcinoma. <i>International Journal of Cancer</i> , 1997 , 74, 523-8	7.5	34
100	Smoothelin expression characteristics: development of a smooth muscle cell in vitro system and identification of a vascular variant. <i>Cell Structure and Function</i> , 1997 , 22, 65-72	2.2	46
99	Conventional bladder wash cytology performed by four experts versus quantitative image analysis. <i>Modern Pathology</i> , 1997 , 10, 976-82	9.8	16
98	Quanticyt: karyometric analysis of bladder washing for patients with superficial bladder cancer. <i>Urology</i> , 1996 , 48, 357-64	1.6	34
97	Prognostic Factors in Prostate Cancer 1996 , 77-85		

96	Loss of chromosome 9 in tissue sections of transitional cell carcinomas as detected by interphase cytogenetics. A comparison with RFLP analysis. <i>Journal of Pathology</i> , 1996 , 179, 169-76	9.4	8
95	Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. <i>Journal of Pathology</i> , 1996 , 180, 295-9	9.4	137
94	Homozygous deletions of p16(INK4) occur frequently in bilharziasis-associated bladder cancer. <i>International Journal of Cancer</i> , 1996 , 68, 183-7	7.5	19
93	The influence of high-energy shock waves on the development of metastases. <i>Ultrasound in Medicine and Biology</i> , 1996 , 22, 339-44	3.5	53
92	The role of cell adhesion molecules and proteases in tumor invasion and metastasis. <i>World Journal of Urology</i> , 1996 , 14, 151-6	4	29
91	p16 mutations/deletions are not frequent events in prostate cancer. <i>British Journal of Cancer</i> , 1996 , 74, 120-2	8.7	35
90	A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization. <i>British Journal of Cancer</i> , 1996 , 74, 573-8	8.7	53
89	HISTOLOGICAL GRADE HETEROGENEITY IN MULTIFOCAL PROSTATE CANCER. BIOLOGICAL AND CLINICAL IMPLICATIONS 1996 , 180, 295		1
88	HISTOLOGICAL GRADE HETEROGENEITY IN MULTIFOCAL PROSTATE CANCER. BIOLOGICAL AND CLINICAL IMPLICATIONS 1996 , 180, 295		6
87	Complex cadherin expression in renal cell carcinoma. <i>Cancer Research</i> , 1996 , 56, 3234-7	10.1	43
86	Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. <i>Cancer Research</i> , 1996 , 56, 4154-8	10.1	144
85	Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer. <i>Clinical Cancer Research</i> , 1996 , 2, 1055-61	12.9	13
84	The effects of successive high-energy shock-wave tumor administration on tumor blood flow. <i>Ultrasound in Medicine and Biology</i> , 1995 , 21, 243-8	3.5	7
83	In vitro proton magnetic resonance spectroscopy of four human prostate cancer cell lines. <i>Prostate</i> , 1995 , 26, 275-80	4.2	13
82	Liarozole, an antitumor drug, modulates cytokeratin expression in the Dunning AT-6sq prostatic carcinoma through in situ accumulation of all-trans-retinoic acid. <i>Prostate</i> , 1995 , 27, 129-40	4.2	20
81	Basic research. <i>International Journal of Urology</i> , 1995 , 2 Suppl 2, 117-21	2.3	
80	Molecular prognostic factors in bladder cancer. <i>World Journal of Urology</i> , 1994 , 12, 84-8	4	21
79	Magnetic resonance spectroscopy detects metabolic differences between seven Dunning rat prostate tumor sublines with different biological behavior. <i>Prostate</i> , 1994 , 25, 19-28	4.2	8

78	Effects of high energy shock waves on tumor blood flow and metabolism: 31P/1H/2H nuclear magnetic resonance study. <i>NMR in Biomedicine</i> , 1994 , 7, 319-26	4.4	4
77	Transcriptional regulation of the human E-cadherin gene in human prostate cancer cell lines: characterization of the human E-cadherin gene promoter. <i>Biochemical and Biophysical Research Communications</i> , 1994 , 203, 1284-90	3.4	64
76	The genes for the calcium-dependent cell adhesion molecules P- and E-cadherin are tandemly arranged in the human genome. <i>Biochemical and Biophysical Research Communications</i> , 1994 , 203, 1291-4	2.4	44
75	p53 mutations have no additional prognostic value over stage in bladder cancer. <i>British Journal of Cancer</i> , 1994 , 70, 496-500	8.7	41
74	Antitumoral effects of liarozole in androgen-dependent and independent R3327-Dunning prostate adenocarcinomas. <i>Journal of Urology</i> , 1994 , 151, 217-22	2.5	36
73	High energy shock waves induced increase in the local concentration of systemically given TNF-alpha. <i>Journal of Urology</i> , 1994 , 152, 2164-6	2.5	5
72	Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. <i>Cancer Research</i> , 1994 , 54, 3929-33	10.1	350
71	Defective E-cadherin function in urological cancers: clinical implications and molecular mechanisms. <i>Invasion & Metastasis</i> , 1994 , 14, 71-81		14
70	Karyometric analysis of intra-tumour heterogeneity in prostate adenocarcinoma. <i>Analytical Cellular Pathology</i> , 1994 , 7, 153-70		1
69	Therapeutic Applications of Monoclonal Antibodies in Combination with Cytokines in Renal Cell Carcinoma 1994 , 132-140		
68	Biological effects of high energy shock waves in mouse skeletal muscle: correlation between 31P magnetic resonance spectroscopic and microscopic alterations. <i>Ultrasound in Medicine and Biology</i> , 1993 , 19, 399-409	3.5	7
67	Characterization of human prostate cancer, benign prostatic hyperplasia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy. <i>Journal of Urology</i> , 1993 , 150, 2019-24	2.5	87
66	Antitumor effects of bacillus Calmette-Guerin in a syngeneic rat bladder tumor model system, RBT323. <i>Journal of Urology</i> , 1993 , 149, 179-82	2.5	8
65	Prognostic value of karyometric and clinical characteristics in renal cell carcinoma. Quantitative assessment of tumor heterogeneity. <i>Cancer</i> , 1993 , 72, 2667-74	6.4	28
64	The rat bladder tumor model system RBT resembles phenotypically and cytogenetically human superficial transitional cell carcinoma. <i>Urological Research</i> , 1993 , 21, 413-21		11
63	Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: biological significance and clinical implications. <i>Cancer and Metastasis Reviews</i> , 1993 , 12, 29-37	9.6	73
62	Molecular cloning and characterization of the human E-cadherin cDNA. <i>Molecular Biology Reports</i> , 1993 , 17, 123-8	2.8	93
61	Image analysis in superficial transitional cell carcinoma of the bladder. <i>Seminars in Urology</i> , 1993 , 11, 164-70		6

60	Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. <i>Cancer Research</i> , 1993 , 53, 5512-6	10.1	97
59	Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. <i>Cancer Research</i> , 1993 , 53, 3241-5	10.1	237
58	Magnetic Resonance Spectroscopic Evaluation of the Effects of High-Energy Shock Waves Administered to a Human Kidney Cancer Xenograft 1993 , 34-39		
57	Antitumorale Wirkungen immuntherapeutischer Agenzien in vitro und in vivo in einem syngenem Tiermodell des Nierenzellkarzinoms 1993 , 62-71		
56	Genetische Schritte in Zusammenhang mit der Entstehung des Prostatakarzinoms 1993 , 151-165		
55	Quantitative light microscopy in urological oncology. <i>Journal of Urology</i> , 1992 , 148, 1-13	2.5	36
54	Inhibition of rat bladder tumor (RBT323) growth by tumor necrosis factor alpha and interferon-gamma in vivo. <i>Journal of Urology</i> , 1992 , 148, 458-62	2.5	6
53	Increased expression of retroviral sequences in progressionally advanced rat prostatic tumors. <i>Biochemical and Biophysical Research Communications</i> , 1992 , 182, 318-24	3.4	2
52	Differential expression of vimentin in rat prostatic tumors. <i>Biochemical and Biophysical Research Communications</i> , 1992 , 182, 1254-9	3.4	20
51	Identification of new prostate cancer progression markers by differential hybridization analysis. <i>European Urology</i> , 1992 , 21 Suppl 1, 60-5	10.2	1
50	Critical review of the models to study the biologic progression of bladder cancer. <i>Journal of Surgical Oncology</i> , 1992 , 8, 274-8		14
49	Karyometry in recurrent superficial transitional cell tumors of the bladder. <i>Urological Research</i> , 1992 , 20, 375-81		11
48	Karyometry of bladder washings for the follow up of patients with transitional cell carcinoma of the bladder. <i>Progress in Clinical and Biological Research</i> , 1992 , 378, 9-18		1
47	Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. <i>Cancer Research</i> , 1992 , 52, 6182-7	10.1	136
46	Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. <i>Cancer Research</i> , 1992 , 52, 5104-9	10.1	406
45	Decreased expression of E-cadherin in the progression of rat prostatic cancer. <i>Cancer Research</i> , 1992 , 52, 2916-22	10.1	122
44	Establishment and characterization of five new human renal tumor xenografts. <i>American Journal of Pathology</i> , 1992 , 140, 483-95	5.8	17
43	Prediction of Cytokine-Therapy on Basis of Class-I and Class-II MHC Antigen Induction 1992 , 121-133		

42	Androgen receptors in endocrine-therapy-resistant human prostate cancer. <i>International Journal of Cancer</i> , 1991 , 48, 189-93	7.5	312
41	HLA-class-I and -class-II expression on renal tumor xenografts and the relation to sensitivity for alpha-IFN, gamma-IFN and TNF. <i>International Journal of Cancer</i> , 1991 , 48, 709-16	7.5	21
40	H-ras expression, genetic instability, and acquisition of metastatic ability by rat prostatic cancer cells following v-H-ras oncogene transfection. <i>Prostate</i> , 1991 , 18, 163-72	4.2	28
39	Differential antiproliferative activities of alpha- and gamma-interferon and tumor necrosis factor alone or in combinations against two prostate cancer xenografts transplanted in nude mice. <i>Prostate</i> , 1991 , 18, 331-44	4.2	20
38	Use of animal models in diagnosis and treatment of renal cell carcinoma. <i>World Journal of Urology</i> , 1991 , 9, 192-197	4	2
37	Oncogene expression in prostate cancer. <i>World Journal of Urology</i> , 1991 , 9, 58-63	4	9
36	Image analysis and grading of prostate adenocarcinoma. <i>World Journal of Urology</i> , 1991 , 9, 86-94	4	1
35	Differential sensitivity of renal cell carcinoma xenografts towards therapy with interferon-alpha, interferon-gamma, tumor necrosis factor and their combinations. <i>Urological Research</i> , 1991 , 19, 91-8		17
34	Effects of high-energy shock waves combined with biological response modifiers in different human kidney cancer xenografts. <i>Ultrasound in Medicine and Biology</i> , 1991 , 17, 391-9	3.5	31
33	Early metabolic response to high energy shock waves in a human tumor kidney xenograft monitored by 31P magnetic resonance spectroscopy. <i>Ultrasound in Medicine and Biology</i> , 1991 , 17, 791-807	3.5	19
32	Cytotoxic effects of high energy shock waves in different in vitro models: influence of the experimental set-up. <i>Journal of Urology</i> , 1991 , 145, 171-5	2.5	37
31	Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differential hybridization analysis. <i>Cancer Research</i> , 1991 , 51, 606-11	10.1	76
30	Cytokeratin expression patterns in metastatic transitional cell carcinoma of the urinary tract. An immunohistochemical study comparing local tumor and autologous metastases. <i>American Journal of Pathology</i> , 1991 , 139, 1389-400	5.8	29
29	Interferon and Tumor Necrosis Factor in Renal Cell Carcinoma Model Systems 1991 , 47-55		
28	Antitumor Effects of High-Energy Shock Waves are Potentiated by Doxorubicin and Biological Response Modifiers 1991 , 228-237		
27	Synergistische antiproliferative Wirkungen des rekombinanten Ratten-Gamma-Interferon und des humanen Tumor Nekrose Faktor Alpha in einem Rattennierenzellkarzinom-Modell. <i>Aktuelle Urologie</i> , 1990 , 21, 109-115	0.4	2
26	In vivo effects of high energy shock waves on urological tumors: an evaluation of treatment modalities. <i>Journal of Urology</i> , 1990 , 144, 785-9	2.5	45
25	In vivo antiproliferative effects of gamma-interferon and tumor necrosis factor alpha in a rat renal cell carcinoma model system. <i>Journal of Urology</i> , 1990 , 143, 1247-51	2.5	13

24	Effects of high-energy shock waves combined with biological response modifiers or Adriamycin on a human kidney cancer xenograft. <i>Urological Research</i> , 1990 , 18, 419-24		22
23	Allelic loss of chromosomes 16q and 10q in human prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990 , 87, 8751-5	11.5	404
22	Oncogene expression in prostate cancer. <i>Progress in Clinical and Biological Research</i> , 1990 , 357, 97-105		2
21	The in vitro effect of electromagnetically generated shock waves (Lithostar) on the Dunning R3327 PAT-2 rat prostatic cancer cell-line. A potentiating effect on the in vitro cytotoxicity of vinblastin. <i>Urological Research</i> , 1989 , 17, 13-9		46
20	Intermediate filament expression and the progression of prostatic cancer as studied in the Dunning R-3327 rat prostatic carcinoma system. <i>Prostate</i> , 1989 , 14, 323-39	4.2	24
19	In Vitro Sensitivity of Three Human Renal Tumor Xenografts Towards Tumor Necrosis Factor and Alpha and Gamma Interferon 1989 , 30-38		2
18	Oncogenes and urological malignancies: implications for the future. <i>Urological Research</i> , 1988 , 16, 333-9		2
17	In vitro antiproliferative efficacy of interferon-alpha, -gamma and tumor necrosis factor on two human renal tumor xenografts. <i>Urological Research</i> , 1988 , 16, 309-14		10
16	Effect of alpha- and gamma-interferon and tumor necrosis factor on colony formation of two human renal tumor xenografts in vitro. <i>Journal of Surgical Oncology</i> , 1988 , 4, 195-8		5
15	Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration. <i>Prostate</i> , 1988 , 13, 25-38	4.2	143
14	Down modulation of fibronectin messenger RNA in metastasizing rat prostatic cancer cells revealed by differential hybridization analysis. <i>Cancer Research</i> , 1988 , 48, 2042-6	10.1	27
13	Genetic organization of the c-sis transcription unit. <i>Nucleic Acids Research</i> , 1987 , 15, 959-70	20.1	23
12	Analysis of a cDNA clone expressing a human autoimmune antigen: full-length sequence of the U2 small nuclear RNA-associated B" antigen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1987 , 84, 2421-5	11.5	114
11	Expression of proto-oncogenes in xenografts of human renal cell carcinomas. <i>Urological Research</i> , 1987 , 15, 349-53		3
10	Structure of the feline c-fes/fps proto-oncogene: genesis of a retroviral oncogene. <i>Journal of Virology</i> , 1987 , 61, 2009-16	6.6	26
9	fur gene expression as a discriminating marker for small cell and nonsmall cell lung carcinomas. <i>Journal of Clinical Investigation</i> , 1987 , 80, 1545-9	15.9	132
8	Expression of the human fes cellular oncogene in renal cell tumors. <i>Urological Research</i> , 1986 , 14, 123-7		12
7	Characterization of human c-fes/fps reveals a new transcription unit (fur) in the immediately upstream region of the proto-oncogene. <i>Molecular Biology Reports</i> , 1986 , 11, 117-25	2.8	85

6	Structure and nucleotide sequence of the 5' region of the human and feline c-sis proto-oncogenes. <i>Nucleic Acids Research</i> , 1986 , 14, 765-78	20.1	26
5	Evolutionary conserved close linkage of the c-fes/fps proto-oncogene and genetic sequences encoding a receptor-like protein. <i>EMBO Journal</i> , 1986 , 5, 2197-202	13	57
4	Molecular cloning of the feline c-fes proto-oncogene and construction of a chimeric transforming gene. <i>Gene</i> , 1985 , 35, 33-43	3.8	6
3	Characterization of the feline c-abl proto-oncogene. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1985 , 824, 104-12		12
2	Comparative analysis of the human and feline c-sis proto-oncogenes. Identification of 5' human c-sis coding sequences that are not homologous to the transforming gene of simian sarcoma virus. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1985 , 825, 140-7		16
1	The structure of the human c-fes/fps proto-oncogene. <i>EMBO Journal</i> , 1985 , 4, 2897-903	13	43